-
Something wrong with this record ?
Pharmacological aspects of cognitive impairment - past, present and future of drugs in dementia
Kathleen Isensee, Georg Petroianu, Holger Stark
Language English Country Czech Republic
NLK
Free Medical Journals
from 2003 to 2013
Freely Accessible Science Journals
from 2003 to 2013
ROAD: Directory of Open Access Scholarly Resources
from 2002
- MeSH
- Amyloid beta-Peptides adverse effects MeSH
- Cholinesterase Inhibitors therapeutic use MeSH
- Drug Therapy MeSH
- Drug Combinations MeSH
- Cognition Disorders history etiology drug therapy MeSH
- Humans MeSH
- Disease Models, Animal MeSH
- tau Proteins adverse effects MeSH
- Receptors, Histamine H3 therapeutic use MeSH
- Receptors, N-Methyl-D-Aspartate antagonists & inhibitors therapeutic use MeSH
- Check Tag
- Humans MeSH
Cognitive impairment is a dramatically increasing problem affecting many individuals as well as the health system. As we have no causal treatment for the loss of memory, symptomatic treatment is needed. Influencing the ACh system is a generally accepted approach, although other therapeutic treatments are in various stages of development. The multiple target drug approach using hybrid compounds may be another optimized move forward for the treatment of cognitive disorders. - Since the complex neuronal regulation is slowly being decoded, there is hope that ways will be found to stop neuronal loss and to generate new synapses.
References provided by Crossref.org
Lit.: 97
- 000
- 02479naa 2200421 a 4500
- 001
- bmc07502304
- 003
- CZ-PrNML
- 005
- 20111210121410.0
- 008
- 080306s2007 xr e eng||
- 009
- AR
- 024 7_
- $a 10.32725/jab.2007.008 $2 doi
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Isensee, Kathleen
- 245 10
- $a Pharmacological aspects of cognitive impairment - past, present and future of drugs in dementia / $c Kathleen Isensee, Georg Petroianu, Holger Stark
- 314 __
- $a Johann Wolfgang Goethe-Universität, Institut für Pharmazeutische Chemie, ZAFES/CMP, Frankfurt/Main
- 504 __
- $a Lit.: 97
- 520 9_
- $a Cognitive impairment is a dramatically increasing problem affecting many individuals as well as the health system. As we have no causal treatment for the loss of memory, symptomatic treatment is needed. Influencing the ACh system is a generally accepted approach, although other therapeutic treatments are in various stages of development. The multiple target drug approach using hybrid compounds may be another optimized move forward for the treatment of cognitive disorders. - Since the complex neuronal regulation is slowly being decoded, there is hope that ways will be found to stop neuronal loss and to generate new synapses.
- 650 _2
- $a kognitivní poruchy $x dějiny $x etiologie $x farmakoterapie $7 D003072
- 650 _2
- $a cholinesterasové inhibitory $x terapeutické užití $7 D002800
- 650 _2
- $a receptory N-methyl-D-aspartátu $x antagonisté a inhibitory $x terapeutické užití $7 D016194
- 650 _2
- $a amyloidní beta-protein $x škodlivé účinky $7 D016229
- 650 _2
- $a proteiny tau $x škodlivé účinky $7 D016875
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a farmakoterapie $7 D004358
- 650 _2
- $a receptory histaminu H3 $x terapeutické užití $7 D018100
- 650 _2
- $a fixní kombinace léků $7 D004338
- 650 _2
- $a lidé $7 D006801
- 700 1_
- $a Petroianu, Georg
- 700 1_
- $a Holger, Stark
- 773 0_
- $w MED00012667 $t Journal of applied biomedicine $g Roč. 5, č. 2 (2007), s. 57-70 $x 1214-021X
- 856 41
- $u https://jab.zsf.jcu.cz/pdfs/jab/2007/02/01.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b B 2301 $c 1249 $y 1
- 990 __
- $a 20080306093114 $b ABA008
- 991 __
- $a 20080325133142 $b ABA008
- 999 __
- $a ok $b bmc $g 617924 $s 470356
- BAS __
- $a 3
- BMC __
- $a 2007 $b 5 $c 2 $d 57-70 $i 1214-021X $m Journal of Applied Biomedicine $x MED00012667
- LZP __
- $a 2007-22/mkal
